Evidence map›Paper›PMID 25356997›Full record

ArticlePloS one2014

Enlarging the toolbox for allergen epitope definition with an allergen-type model protein.

Hanna Berkner, Christian Seutter von Loetzen, Maximilian Hartl, Stefanie Randow, Michaela Gubesch, Lothar Vogel, Felix Husslik, Andreas Reuter, Jonas Lidholm, Barbara Ballmer-Weber and 3 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Recombinant Allergens in Structural Biology, Diagnosis, and Immunotherapy.International archives of allergy and immunology · 2017
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 3 countries.

Hanna BerknerDepartment of Biopolymers, University of Bayreuth, Bayreuth, Bavaria, Germany.
Christian Seutter von LoetzenDepartment of Biopolymers, University of Bayreuth, Bayreuth, Bavaria, Germany.
Maximilian HartlDepartment of Biopolymers, University of Bayreuth, Bayreuth, Bavaria, Germany.
Stefanie RandowDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Michaela GubeschDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Lothar VogelDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Felix HusslikDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Andreas ReuterDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Jonas LidholmImmunoDiagnostics Division, Thermo Fisher Scientific Inc., Uppsala, Uppsala län, Sweden.
Barbara Ballmer-WeberDepartment of Dermatology, Allergy Unit, University Hospital Zürich, Zürich, Zürich, Switzerland.
Stefan ViethsDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Paul RöschDepartment of Biopolymers, University of Bayreuth, Bayreuth, Bavaria, Germany.
Dirk SchillerDivision of Allergology, Paul-Ehrlich-Institut, Langen, Hesse, Germany.
Paul Ehrlich Institut · DEUniversity of Bayreuth · DEThermo Fisher Scientific (Sweden) · SEUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBirch pollen-allergic subjects produce polyclonal cross-reactive IgE antibodies that mediate pollen-associated food allergies. The major allergen Bet v 1 and its homologs in plant foods bind IgE in their native protein conformation. Information on location, number and clinical relevance of IgE epitopes is limited. We addressed the use of an allergen-related protein model to identify amino acids critical for IgE binding of PR-10 allergens.

methodNorcoclaurine synthase (NCS) from meadow rue is structurally homologous to Bet v 1 but does not bind Bet v 1-reactive IgE. NCS was used as the template for epitope grafting. NCS variants were tested with sera from 70 birch pollen allergic subjects and with monoclonal antibody BV16 reported to compete with IgE binding to Bet v 1.

resultsWe generated an NCS variant (Δ29NCSN57/I58E/D60N/V63P/D68K) harboring an IgE epitope of Bet v 1. Bet v 1-type protein folding of the NCS variant was evaluated by 1H-15N-HSQC NMR spectroscopy. BV16 bound the NCS variant and 71% (50/70 sera) of our study population showed significant IgE binding. We observed IgE and BV16 cross-reactivity to the epitope presented by the NCS variant in a subgroup of Bet v 1-related allergens. Moreover BV16 blocked IgE binding to the NCS variant. Antibody cross-reactivity depended on a defined orientation of amino acids within the Bet v 1-type conformation.

conclusionOur system allows the evaluation of patient-specific epitope profiles and will facilitate both the identification of clinically relevant epitopes as biomarkers and the monitoring of therapeutic outcomes to improve diagnosis, prognosis, and therapy of allergies caused by PR-10 proteins.

Indexed as

AllergensAmino Acid SequenceAntigens, PlantBinding SitesCross ReactionsEpitopesHumansImmunoglobulin EImmunoglobulin GModels, MolecularMolecular Sequence DataMutant ProteinsPlant ProteinsProtein BindingProtein Structure, TertiarySequence Homology, Amino AcidAllergensAntigens, PlantBet v 1 allergen, BetulaEpitopesImmunoglobulin EImmunoglobulin GMutant ProteinsPlant Proteins

Identifiers

PMID25356997
PMCPMC4214763
OpenAlexW2023882541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.